Overview
A monoplace chamber is a hyperbaric unit designed to treat one patient at a time. The patient lies inside a transparent cylindrical shell that is pressurised with 100% medical-grade oxygen. These chambers typically operate between 2.0 and 3.0 atmospheres absolute (ATA) and are the dominant configuration in US hospital-based hyperbaric medicine.
Monoplace chambers are the workhorse of US clinical hyperbaric medicine. A typical hospital hyperbaric programme runs between two and twelve monoplace units in a single clinic, treating diabetic ulcers, radiation injury, compromised grafts, and other UHMS-approved wound-care indications throughout the day. Each unit is operated by a certified hyperbaric technologist (CHT) with a hyperbaric physician immediately available.
The chamber itself is a cylindrical acrylic or steel-and-acrylic shell approximately 7–8 feet long and 32–36 inches in diameter. The patient enters feet-first on a sliding stretcher, lies supine, and is sealed inside the chamber for the duration of the session. Visibility through the clear acrylic shell is important for both patient comfort and clinical observation.
How It Works
The chamber is pressurised with 100% medical-grade oxygen flowing through the chamber environment, so the patient breathes the ambient atmosphere directly without masks or hoods. Compression typically takes 10–15 minutes from sea-level pressure to the treatment depth (2.0–2.4 ATA for most indications). At pressure, dissolved oxygen in the patient's blood plasma rises more than ten-fold compared with normal atmospheric breathing, driving the therapeutic effects of HBOT — angiogenesis, HIF-1α stabilisation, antimicrobial activity, and tissue oxygen delivery to hypoperfused regions.
Specifications
| Pressure range | 1.5–3.0 ATA |
|---|---|
| Oxygen purity | 100% O₂ |
| Session duration | 60–120 minutes |
| Typical cost | $150,000–$300,000 (clinical-grade) |
Clinical Uses
- Wound care (diabetic foot ulcer, chronic refractory osteomyelitis, compromised skin grafts, delayed radiation injury) — the largest clinical use case.
- Carbon monoxide poisoning (acute) — Weaver protocol delivers 3.0 ATA then 2.0 ATA across three sessions.
- Decompression sickness and arterial gas embolism — US Navy Treatment Table 6 at 2.8 ATA.
- Neurological research protocols (TBI, stroke, long COVID) — the Efrati Lab 2.0 ATA / 40-session course is typically delivered in monoplace units.
- Sudden sensorineural hearing loss — a CMS-covered indication added in 2021.
Patient Experience
Patients lie supine on a padded stretcher inside the clear chamber. Most facilities provide an audio system for music or audiobooks, and some offer a TV screen viewable through the chamber shell. Patients can communicate with the operator via intercom at any time. The main sensations during compression are mild ear fullness (relieved by Valsalva or Toynbee equalisation) and gentle warming of the chamber air. At treatment depth the environment is quiet and most patients find the experience restful; many sleep. Decompression produces a mild cooling and ear fullness in reverse.
Pros & Cons
Advantages
- Lower capital cost than multiplace ($150K–$300K vs $500K–$2M+).
- Simpler staffing — one technologist can supervise a bank of chambers.
- Patient isolation — reduces infection control concerns.
- Standard configuration for US clinical HBOT; well-established workflow.
Limitations
- Cannot deliver critical-care HBOT easily — no attendant inside with the patient.
- Confined feeling may trigger claustrophobia in a minority of patients.
- Patient volumes limited by number of chambers; multiplace is more throughput-efficient at scale.
- All equipment inside the chamber must be hyperbaric-rated — restricts in-chamber medical interventions.
Cost & Access
A clinical-grade monoplace chamber costs approximately $150,000–$300,000 to purchase and install. Facility costs (reinforced room, oxygen supply, gas-handling infrastructure, HVAC) add $100,000–$300,000 to the installed cost. Per-session Medicare reimbursement in the US is approximately $450 at UHMS-accredited hospital facilities, with physician supervision billed separately (CPT 99183). Off-label cash-pay HBOT in private clinics ranges $150–$450 per session depending on region and pressure.
Key References
- Thom SR et al. (2006) — Stem cell mobilisation via HBOT in monoplace chambers, Am J Physiol.
- Löndahl M et al. (2010) — Diabetic foot ulcer healing at 2.5 ATA, Diabetes Care.
- Weaver LK et al. (2002) — Carbon monoxide poisoning protocol, NEJM.
- Hadanny A, Efrati S (2020) — Neurological HBOT at 2.0 ATA, Nature review.
Frequently Asked Questions
Is a monoplace chamber safe?
Monoplace chambers have an excellent safety profile when operated by trained staff. The most common adverse event is middle-ear barotrauma (2–15% of patients) which is usually self-limited. CNS oxygen toxicity seizures are rare (~1 in 10,000 sessions) and preventable with proper screening and air breaks.
Can I claustrophobe inside a monoplace chamber?
A minority of patients experience confinement anxiety. The transparent shell allows visibility out of the chamber, which helps most patients. Options for severe claustrophobia include anxiolysis, gradual-exposure conditioning sessions, or treatment in a multiplace chamber instead.
What is the difference between monoplace and multiplace?
Monoplace: single patient, chamber pressurised with 100% oxygen. Multiplace: multiple patients, chamber pressurised with air while patients breathe oxygen via mask or hood. At the same pressure both deliver clinically equivalent HBOT; the choice depends on facility logistics and patient needs.
How long is a session?
Typical sessions run 90–120 minutes total — 10–15 minutes for compression, 60–90 minutes at treatment pressure (with scheduled 5-minute air breaks every 20–30 minutes), and 10–15 minutes for decompression.
Research disclaimer: This reference is for educational purposes only. HBOT is a regulated medical treatment that must be administered under appropriate professional supervision. Always consult a qualified physician before considering hyperbaric therapy. Information reflects published research and regulatory guidance available at the time of review.